Данный веб-сайт использует cookie-файлы. Вы принимаете использование внешних cookie-файлов? Да Нет Узнать больше x
Опрос об ахондроплазии
Мы разработали вопросник с целью лучше узнать о людях, связанных с ахондроплазией.
Этот вопросник является необязательным и анонимным.
Полученные данные будут использоваться для статистических целей и лучшего понимания естественного развития ахондроплазии. Пожалуйста, обдумайте ответы.

Если вы хотите принять участие в опросе позже, вы можете нажать на ссылку в верхней части «Регистрация».

QED Therapeutics (an affiliate of BridgeBio) has announced the results of a clinical trial group from the PROPEL 2 Study, a Phase 2 trial of infigratinib for children with achondroplasia. See press release.

The data* revealed show interesting results and no treatment-related adverse effects. According to the company:

  • There was an average increase in annual growth velocity in height of +2.51 cm at 12 months, and +2.50 cm at 18 months.
  • A reduction in body disproportionality was also observed, from 2.02 to 1.88 at month 18.
  • Infigratinib showed a continuous and well-tolerated safety profile, with no treatment-related adverse events evaluated.

*The key results can be seen here.

 


What is body proportionality?


It consists of the ratio between the upper and lower segments of the body. It is calculated using the formula "sitting height / (standing height - sitting height)", and is approximately 2 in children with achondroplasia. In children with development within the growth curves, the proportionality is 1. In the image below, you can see the scatter plots and cubic quantile regression curves of the upper/lower body segment ratio from birth to 15 years in (A) female children and (B) male children:

graf infigratinib jul24

Scatter plots of the ratio between upper and lower body segments
Source: Savarirayan, R., Irving, M., Harmatz, P., Delgado, et al. (2022). Growth parameters in children with achondroplasia: A 7-year, prospective, multinational, observational study. Genetics in Medicine, 24(12), 2444-2452.
https://doi.org/10.1016/j.gim.2022.08.015.

Know more: what is Infigratinib?
Infigratinib is an oral molecule (drug in development) designed to inhibit the signaling of the FGFR3 gene, acting on the cause of achondroplasia.


Find more information about QED's ongoing achondroplasia studies by following the links below:

  1. PROPEL (NCT04035811)

    Observational study of initiation for children with achondroplasia

    open

  2. PROPEL 2 (NCT04265651)

    Phase 2 study for children with achondroplasia (registration complete)

    open

  3. PROPEL 3 (NCT06164951)

    Phase 3 study for children with achondroplasia

    open

  4. PROPEL OLE (NCT05145010)

    Open extension study for children with achondroplasia

    open

Для просмотра этого сайта требуется Internet Explorer 8 (или более поздняя версия)
или другой Интернет-браузер.


Спасибо